Abstract
Cough is one of the most frequent symptoms of the new coronavirus infection (COVID-19). It reduces the quality of life and contributes to the development of life-threatening conditions.Aim. This article analyzes modern approaches to the pharmacotherapy of cough in patients with the new coronavirus infection from the standpoint of pathogenetic justification of the use of drugs. The main mechanisms of cough development in COVID-19 presented in the literature are considered. The cough is associated with virus-induced damage to the epithelium and subsequent release of biologically active substances that irritate the afferent endings of the vagus nerve. Approaches to cough management in COVID-19 with the possible use of antitussive (central and peripheral action) and mucoactive drugs (expectorants, mucokinetics, mucolytics, mucoregulators) are addressed.Conclusion. Based on the literature data and pathogenesis, antitussive drugs play a crucial role in the treatment of cough in COVID-19.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
